Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review

BackgroundEmicizumab, a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis of bleeding episodes in people with hemophilia A, can impose a significant financial burden. We conducted a systematic review to evaluate the reporting quality of existing pharmacoeconomic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Min Chen, Yunzhu Lin, Guoqian He, Liang Huang, Junyi Han, Jiaqi Ni
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2025-10-01
Col·lecció:Frontiers in Public Health
Matèries:
hemophilia A
emicizumab
cost-effectiveness
systematic review
pharmacoeconomic
Accés en línia:https://www.frontiersin.org/articles/10.3389/fpubh.2025.1658760/full
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars